ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Expanding HER2 horizons: Implications for NSCLC and beyond"
Episode Synopsis
touchPANEL DISCUSSION for touchRESPIRATORY
Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.
The experts
Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA
Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA
Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA
This touchPODCAST is for HCPs outside of the UK only.
This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchrespiratoryime.org/her2_in_solid_tumours_and_nsclc/
Listen to three experts as they explore tissue-agnostic HER2 targeting in solid tumours, the latest clinical trial data for approved and emerging HER2-targeted therapies in NSCLC, and best practices for testing for HER2 alterations in NSCLC.
The experts
Dr Razelle Kurzrock - Medical Oncologist, Medical College of Wisconsin, Milwaukee, WI, USA
Dr Lyudmila Bazhenova - Medical Oncologist, UC San Diego Moores Cancer Center, San Diego, CA, USA
Dr Ignacio Wistuba - Pathologist, MD Anderson Cancer Center, Houston, TX, USA
This touchPODCAST is for HCPs outside of the UK only.
This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchrespiratoryime.org/her2_in_solid_tumours_and_nsclc/
In God we trust